In most transplant centers, transplant surgeons manage the immediate post-operative care; hepatologists are responsible for the long-term post-transplant follow-up. We aimed to evaluate the outcome of all patients who were on regular follow-up at our hepatology clinic for the organ transplantation program. We reviewed files of liver transplant recipients who underwent living liver transplantation at our surgical department, and those who had transplanted abroad before the introduction of our living liver transplantation program. Evidence of rejection, recurrence of the primary disease, and co morbidities were examined. A total of 27 recipients were registered from January 2006 through October 2007, 52% were females. Liver transplant was from live donor in 16 recipients, and from cadaver donor in 11 recipients, surgery was undertaken in different countries (7 in Libya, 20 in other countries). The underlying liver diseases for which liver transplantation was indicated in children were (2 cases of Byler disease, 2 extra hepatic biliary atresia, 2 congenital liver fibrosis, 1 tyrosinemia), and in adults were (5 hepatitis C, 4 hepatitis B, 4 primary sclerosing cholangitis, 2 primary biliary cirrhosis, 2 Wilson disease, 1 autoimmune hepatitis, 1 alcoholic cirrhosis, 1 cryptogenic). 3 patients died within nine months of surgery. 24 recipients are on regular follow up, mean age was 36.6 (range: 2-61) years, post operative duration of 1-19 years (mean 4 years), 6 patients experienced early rejection which was treated successfully, 2 patients developed chronic rejection. Recurrence of the primary disease occurs in 9/24 (37.5%) patients (4 hepatitis C, 2 hepatitis B, 2 primary sclerosing chollangitis, 1 autoimmune hepatitis), immunosuppression was Tacrolimus based in 17/24(71%) recipients, diabetes mellitus developed in 3 patients. Inconclusion, among adult Libyan liver recipients, hepatitis C is the most common indication for liver transplantation with a high recurrence rate. Drug related diabetes mellitus occured in Tacrolimus based immunosuppression.